In May 2025, the WHO Expert Committee on Selection and Use of Essential Medicines convened to update the Model List, reaffirming Ezetimibe's inclusion due to its efficacy in managing cholesterol levels. This decision reflects the ongoing recognition of Ezetimibe's importance in global health.
In January 2026, the NPPA conducted a review of lipid-lowering agents' pricing in India. While Ezetimibe remained outside the DPCO, the review highlighted the need for monitoring price trends to ensure affordability without compromising quality.
In February 2026, the FDA issued updated guidance on bioequivalence studies for generic Ezetimibe formulations, emphasizing the need for robust clinical data to support ANDA approvals. This guidance aims to maintain high standards for generic medications entering the U.S. market.
In March 2026, the EMA released a report on the pharmacovigilance of lipid-lowering agents, including Ezetimibe, noting a favorable benefit-risk profile. The report encouraged continued monitoring to promptly identify and address any emerging safety concerns.
In March 2026, the WHO launched a global repository for National Essential Medicines Lists (nEMLs), providing a centralized platform for countries to share and access information on essential medicines, including Ezetimibe. This initiative aims to harmonize medicine selection and improve access worldwide.
These developments underscore the dynamic regulatory environment surrounding Ezetimibe, highlighting the importance of continuous compliance and vigilance by manufacturers and exporters.
